Mallikarjun Vasam

Dr. Mallikarjun Vasam

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 November 2023 in Biochemistry and Biophysics Reports
Verified
Journal Article
Open access
MVMallikarjun Vasam
Mallikarjun Vasam
SKSatyanarayana Korutla
Satyanarayana Korutla
Raghvendra BoharaRaghvendra Bohara
Raghvendra Bohara
Globally, Acne Vulgaris is a widespread, chronic inflammatory condition of the pilosebaceous follicles. Acne is not fatal, but depending on its severity, it can leave the sufferer with scars, irritation, and significant psychological effects (including depression). In the current review, we have included various factors for acne and their treatment explained. It also narrated the current medicament and the new investigation dosage forms with clinical phases information provided. Acne's pathophysiology involves four important factors: excessive sebum production, hyperkeratinization of pilosebaceous follicles, hyperproliferation of propionibacterium acnes (P. acnes), and inflammation. Identifying both inflammatory (Papule, pustule, nodule, and cyst) and non-inflammatory (black heads, white heads) acne lesions is necessary for diagnosing and treating acne vulgaris. In this review, traditional therapy approaches such as topical (i.e., retinoids and antibiotics), systemic (i.e., retinoids, antibiotics, and hormonal), and physical therapies are briefly discussed. In addition, we highlight the issues posed by P. acne's resistance to the antibiotics used in commercially available medications and the necessity for novel therapeutic techniques. Finally, we examined a few innovative acne therapies pending clinical trial approval and commercial acne medications.

15 November 2022 in Journal of Biomaterials Science, Polymer Edition
Verified
Journal Article
Closed access
MVMallikarjun Vasam
Mallikarjun Vasam
RGRama Krishna Goulikar
Rama Krishna Goulikar
Tuberculosis (TB) is still the biggest infectious disease among adults globally, which effects the social and biological lives of patients as well as the economic liability of healthcare systems. Current treatment regime has challenges with drug resistant (MDR/XDR) strains and the failure of standard therapeutic interventions against these TB strains. In the recent years, several nanocarrier-based drug delivery systems developed (including lipid-based) with anti-tuberculosis drugs via targeted delivery to improve the therapeutic outcomes. In this review, we attempt to summarize on the composition of the reported solid lipid-based particles (SLNPs), their various production methodologies, and properties of the delivery system, and their influence on cellular and pharmacokinetic aspects are also discussed. Besides, we have highlighted anti-TB drugs delivering via lipid-based systems have shown promising outcomes, however clinical translation of such systems is still under investigation. Based on recent advancements and reports, it is recommended that future efforts be made to accelerate the translational development of lipid-based nanocarriers to improve TB treatment.

23 December 2024 in Pharmaceutical Nanotechnology
Verified
Journal Article
Closed access
PDF file
CTchandrashekar Thalluri
chandrashekar Thalluri
MVMallikarjun Vasam
Mallikarjun Vasam
RJRajkumar Jampala
Rajkumar Jampala
SAShanmugarathinam Alagarsamy
Shanmugarathinam Alagarsamy
ADAnubhav Dubey Dubey
Anubhav Dubey Dubey
THTanuj Hooda
Tanuj Hooda
Background: Tapentadol hydrochloride is a potent analgesic commonly used to manage moderate to severe pain. Rapidly dissolving tablets of Tapentadol offer a significant advantage in enhancing patient compliance by providing quick pain relief. The development of fast-dissolving tablets (FDTs) requires careful consideration of formulation parameters to achieve optimal disintegration and dissolution profiles. In this study, the aim was to fabricate Tapentadol FDTs by selecting suitable super disintegrating agents such as croscarmellose sodium and crospovidone, which serve as two independent variables. The direct compression method was employed to formulate nine different Tapentadol hydrochloride formulations (TH1 to TH9). Materials and Methods: The study utilized Design-Expert® software version 13.0 and the Response Surface Methodology (RSM) for the optimization of Tapentadol FDTs. The formulations were prepared using the direct compression method with varying concentrations of the super disintegrants, croscarmellose sodium, and crospovidone. The primary response variables considered in this optimization study included disintegration time (Y1), percentage drug release at 15 minutes (Q15, Y2), and percentage drug release at 30 minutes (Q30, Y3). All pre-compressional and postcompressional parameters were evaluated for each formulation, along with in vitro dissolution studies. Furthermore, DD Solver, a statistical tool, was employed to determine the kinetics of drug release and the release order mechanism based on regression coefficient value (r²), Akaike Information Criterion (AIC), and Model Selection Criteria (MSC). Results: The evaluation studies indicated that the TH5 formulation exhibited the most rapid disintegration time and the highest drug release percentage within the specified time frame. The super disintegrants used demonstrated a significant impact on the response variables, notably enhancing the solubility and dissolution rate of Tapentadol hydrochloride. Based on the exponent release (n) value, the study concluded that the TH5 formulation followed a first-order release kinetics and Fickian diffusion mechanism for drug release. Stability studies were performed following the International Council for Harmonization (ICH) guidelines to assess the shelf-life of the optimized formulation. The ANOVA data revealed that the p-value was greater than 0.05, indicating no significant differences during the storage period. Additionally, a similarity factor (f2) analysis was conducted to compare the optimized formulation with the marketed formulation (Tydol 100 mg). Discussion: The findings highlight the crucial role of super disintegrants in fast-dissolving tablet formulation, significantly impacting disintegration time and dissolution profile. The TH5 formulation excelled in rapid disintegration and drug release, optimized using RSM and Design-Expert software, with statistical analysis confirming the Fickian diffusion mechanism for drug release. Conclusion: The study successfully developed and optimized Tapentadol fast-dissolving tablets using direct compression and response surface methodology. The TH5 formulation showed rapid disintegration and optimal drug release, with stability confirmed under ICH conditions. This highlights the importance of super disintegrants in FDT formulation for rapid action and patient compliance.

1 January 2021
Verified
Book Chapter
Closed access
PDF file
MVMallikarjun Vasam
Mallikarjun Vasam
RPRaja Abhilash Punagoti
Raja Abhilash Punagoti
RMRita Mourya
Rita Mourya

19 December 2023 in Global Journal of Pharmacy & Pharmaceutical Sciences
Verified
Journal Article
Open access
PDF file
MVMallikarjun Vasam
Mallikarjun Vasam
PKPraneeth Rao Kakullamarri
Praneeth Rao Kakullamarri
CTChandrashekar Talluri
Chandrashekar Talluri
SAShanmugarathinam Alagarsamy
Shanmugarathinam Alagarsamy
BMBalaji Maddiboyina
Balaji Maddiboyina
Oral medicine administration is still preferred by many people. But many new drugs are only moderately soluble Racca Cauda [1].

1 June 2024 in Asian Journal of Pharmaceutics
Verified
Journal Article
Open access
PDF file
MVMallikarjun Vasam
Mallikarjun Vasam
The Asian Journal of Pharmaceutics is a peer-reviewed open-access medical journal published by Medknow Publications on behalf of the B.R. Nahata Smriti Sansthan (Memorial Trust) (Mandsaur, India). Articles address topics in pharmaceutics, biopharmaceutics, pharmaceutical chemistry, pharmacognosy, pharmacology, pharmaceutical analysis, pharmacy practice, and clinical and hospital pharmacy.